MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
11 Marzo 2024 - 5:00AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED)
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today that members of the Company’s management
team will host one on one investor meetings at the Leerink Partners
2024 Global Biopharma Conference, which will be held in Miami, FL
from March 11-13, 2024.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the Cboe
Canada (formerly known as the NEO Exchange, Inc.) under the symbol
MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240311308621/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfica de Acción Histórica
De May 2023 a May 2024